Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells
Dr. Peter Coffey from University College London shares his work with the London Project to Cure Blindness, which resulted in the first clinical stem cell trial to treat blindness, and discusses cell quality requirements for clinical trials. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
Dr. Peter Coffey from University College London shares his work with the London Project to Cure Blindness, which resulted in the first clinical stem cell trial to treat blindness, and discusses cell quality requirements for clinical trials. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
Publish Date:
November 01, 2019
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Related Multimedia
-
Nature Research Round Table: Parkinson's Disease Therapy with Human Embryonic Stem Cells
Publish Date: November 01, 2019 -
Nature Research Round Table: Human Pluripotent Stem Cell Lines as Disease Models
Publish Date: November 01, 2019 -
Nature Research Round Table: hPSC Lines for Cell Therapies - Panel Discussion
Publish Date: November 01, 2019
Explore Our Products
-
Defined supplement for single-cell cloning of human ES and iPS cells -
cGMP, animal origin-free, stabilized, feeder-free maintenance medium for human ES and iPS cells -
cGMP, feeder-free maintenance medium for human ES and iPS cells -
qPCR analysis kit for detecting the majority of karyotypic abnormalities reported in human ES and iPS cells
